INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

被引：4
|
作者：
Fujiwara, Yutaka [1 ]
Shitara, Kohei [2 ]
Shimizu, Toshio [1 ]
Yonemori, Kan [1 ]
Matsubara, Nobuaki [2 ]
Ohno, Izumi [2 ]
Kogawa, Takahiro [2 ]
Naito, Yoichi [2 ]
Leopold, Lance [3 ]
Sasahara, Kahori [4 ]
Yatsuzuka, Naoyoshi [4 ]
Takami, Tomoko [4 ]
Shimamoto, Takashi [4 ]
Yamamoto, Noboru [1 ]
Doi, Toshihiko [2 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Incyte Corp, Wilmington, DE USA
[4] MSD KK, Tokyo, Japan
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A204
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study (vol 3, pg 2572, 2023)
    Munster, Pamela
    Iannotti, Nicholas
    Cho, Daniel C.
    Kirkwood, John M.
    Villaruz, Liza C.
    Gibney, Geoffrey T.
    Hodi, F. Stephen
    Mettu, Niharika B.
    Jones, Mark
    Bowman, Jill
    Smith, Michael
    Lakshminarayanan, Mani
    O'Day, Steven
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (03): : 785 - 785
  • [32] Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors
    Cho, B. C.
    Perets, R.
    Bar, J.
    Ahn, M-J.
    Kim, D-W.
    Yoh, K.
    Nagrial, A.
    Spigel, D. R.
    Lee, D. H.
    Gutierrez, M.
    Kotasek, D.
    Siddiqi, S.
    Chain, A.
    Butts, B. D.
    Zhang, Y.
    Li, X.
    Cyrus, J.
    Tse, A.
    Altura, R. A.
    Rasco, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Final results of a Phase I study of cediranib, a VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Murakami, H.
    Yamamoto, N.
    Boku, N.
    Yamazaki, K.
    Yamamoto, N.
    Yamada, Y.
    Yamada, K.
    Puchalski, T.
    Shin, E.
    Tamura, T.
    EJC SUPPLEMENTS, 2008, 6 (12): : 124 - 124
  • [34] Phase 1 first-in-human study of anti-ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results
    Gutierrez, Martin
    Spreafico, Anna
    Wang, Ding
    Golan, Talia
    Renouf, Daniel
    Voskoboynik, Mark
    Chatterjee, Manash Shankar
    Kapadia, Kishan J.
    Liu, Qi
    Kovvali, Gopala
    Suttner, Leah
    Pang, Ling
    Chen, Mei
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors
    Bendell, J.
    Lager, J.
    Zafar, Y.
    Yu, D.
    George, D.
    Nixon, A.
    Petros, W.
    Arrowood, C.
    Beci, R.
    Hurwitz, H.
    ANNALS OF ONCOLOGY, 2006, 17 : 67 - 67
  • [36] Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
    Toshihiko Doi
    Yutaka Fujiwara
    Nobuaki Matsubara
    Junichi Tomomatsu
    Satoru Iwasa
    Akari Tanaka
    Chihiro Endo-Tsukude
    Shintaro Nakagawa
    Shunji Takahashi
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 393 - 404
  • [37] Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Fujiwara, Yutaka
    Matsubara, Nobuaki
    Tomomatsu, Junichi
    Iwasa, Satoru
    Tanaka, Akari
    Endo-Tsukude, Chihiro
    Nakagawa, Shintaro
    Takahashi, Shunji
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 393 - 404
  • [38] First-in-human phase I study of ABBV-637 as monotherapy and in combination in patients with relapsed and refractory solid tumors
    Rotow, J.
    Yoh, K.
    Powderly, J. D.
    Shimizu, T.
    Perets, R.
    Paz-Ares, L.
    Phillips, A.
    Souers, A.
    Ansell, P. J.
    Jin, J.
    Badawi, M.
    Saab, R.
    Morrison-Thiele, G.
    Jeffries, S.
    Aristide, M. R. Neagu
    Carneiro, B. A.
    Papadopoulos, K. P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1090 - S1090
  • [39] Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC
    Kurata, Takayasu
    Nakagawa, Kazuhiko
    Satouchi, Miyako
    Seto, Takashi
    Sawada, Takeshi
    Han, Shi Rong
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nogami, Naoyuki
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Phase I study of the arginase inhibitor INCB001158(1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
    Naing, A.
    Bauer, T.
    Papadopoulos, K. P.
    Rahma, O.
    Tsai, F.
    Garralda, E.
    Naidoo, J.
    Pai, S.
    Gibson, M. K.
    Rybkin, I.
    Wang, D.
    McDermott, D. F.
    Fasolo, A.
    de Miguel, M.
    Shaheen, M.
    Jenkins, Y.
    Kallender, H.
    Gogov, S.
    Kuriakose, E.
    Pishvaian, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 160 - 160
12345